Member Info for beechknot

High volume buying today .Buyers taking positions ,2 good rns in 30 days ,New in house sales team .P O C test ,Nice progress gdr .

Which ever reason such buying ,Buys replacing sells so Quickly .Buys seeing such momentum .

Speed sellers been replaced with more buys ,Are the sellers wanting shares before C O B ,
45 to 50 C O B

Lunch time ,yet buying volume ,Bodes well for large move up Afternoon buyers not risking being out for next week .

Volume of buys ,Speed sells bought up ,with progress at gdr ,P O C ,Are many prepared to risk being out over weekend ,Are many buyers wanting shares before C O B today .

Yesterdays tweet ,New sales team , Such good timing P OC ready .good rns last 30 days ,

RNS is it close ,Are there higher odds for next week , 2 good poc rns last 30 days ,

Rocket building .

2 RNS in 30 days , Well read up people aware number of different rns due .Even if no rns today ,Are many prepared to risk being out over weekend .

Updating by Twitter , 2 excellent rns in 30 days . The number of rns due ,Encouraging to see the changes at gdr .

Well done to gdr now in house sales team . thy now updating with Twitter as seen yesterday .
2 excellent rns in last Month .

When rns if 50 or 60 so fast .who wanna miss out for a few pence .

More demand for poc if pcr used less .
RNS could drop at any time ,who wanna be out .

Information about the Genedrive® instrument and the new Genedrive® COV19-ID Kit can be found at http://www.genedrive.com/assays/cov19-id-assay.php



The Company's initial commercial focus is the European Union, utilising the regulatory clearance of CE marking, and will be followed by the UK. The registration processes in the UK require a larger sample set than for CE marking and submission under CTDA legislation. The Company is actively recruiting patient samples for these expanded requirements, which is proceeding well.



David Budd, CEO of genedrive plc, said: "I am delighted to say that development work from the Company has resulted in designing and delivering a product with excellent performance specifications and a speed to result that is a new benchmark. The new Genedrive® COV19-ID Kit combines the speed and ease of lateral flow testing with molecular level accuracy in a low cost and portable device. We are now able to progress the commercial evaluations of the product to selected partners and given its performance in our studies, we believe there remain substantial market opportunities that can be targeted. As recent news of the Omicron variant demonstrates, COVID-19 remains a significant issue in global health and thus rapid and accurate testing will remain a critical tool in managing the spread of the virus."



The Company is seeking commercial partners in some specific EU countries. Potential partners can register their interest via info@genedrive.com

They buy up sells ,they no risk missing out for a few pence if rns .

Who prepared to be out if rns .

Expect upward movement ,

Numerous buyers not wanting to be out if rns ,

Encouraging o see gdr update Twitter ,Blue soon , Are people prepared to risk being out if rns .

David Budd and team congratulations to them for poc

Encouraging to see quantity of buys replacing sells .